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ORIGINAL RESEARCH
Umbilical cord blood CD34C progenitor-derived NK cells efﬁciently kill ovarian cancer
spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice
Janneke S. Hoogstad-van Everta,b, Jeannette Canya, Dirk van den Brandc, Manon Oudenampsena, Roland Brockc,
Ruurd Torensmad, Ruud L. Bekkersb, Joop H. Jansena, Leon F. Massugerb, and Harry Dolstraa
aDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands; bDepartment of
Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands; cDepartment of Biochemistry, Radboud University Medical
Center, Nijmegen, the Netherlands; dDepartment of Tumor Immunology, Radboud University Medical Center, Nijmegen, the Netherlands
Key Points
1. HSPC-NK cells efﬁciently destruct ovarian carcinoma spheroids in vitro and target intraperitoneal ovarian tumors in vivo.
2. HSPC-NK cells actively migrate, inﬁltrate and mediate intratumoral cell killing in a three-dimensional ovarian cancer spheroid.
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ABSTRACT
Adoptive transfer of allogeneic natural killer (NK) cells is an attractive therapy approach against ovarian
carcinoma. Here, we evaluated the potency of highly active NK cells derived from human CD34C
haematopoietic stem and progenitor cells (HSPC) to inﬁltrate and mediate killing of human ovarian cancer
spheroids using an in vivo-like model system and mouse xenograft model. These CD56CPerforinC HSPC-
NK cells were generated under stroma-free conditions in the presence of StemRegenin-1, IL-15, and IL-12,
and exerted efﬁcient cytolytic activity and IFNg production toward ovarian cancer monolayer cultures.
Live-imaging confocal microscopy demonstrated that these HSPC-NK cells actively migrate, inﬁltrate, and
mediate tumor cell killing in a three-dimensional multicellular ovarian cancer spheroid. Inﬁltration of up to
30% of total HSPC-NK cells within 8 h resulted in robust tumor spheroid destruction. Furthermore,
intraperitoneal HSPC-NK cell infusions in NOD/SCID-IL2Rgnull (NSG) mice bearing ovarian carcinoma
signiﬁcantly reduced tumor progression. These ﬁndings demonstrate that highly functional HSPC-NK cells
efﬁciently destruct ovarian carcinoma spheroids in vitro and kill intraperitoneal ovarian tumors in vivo,
providing great promise for effective immunotherapy through intraperitoneal HSPC-NK cell adoptive








Ovarian cancer (OC) is the ﬁfth leading cause of cancer-related
death in women.1 Since patients with early-stage OC seldom
have clinical symptoms, most patients are diagnosed at
advanced stage with peritoneal tumor dissemination and asci-
tes. Standard treatment of OC patients is cytoreductive surgery
combined with platinum/taxane chemotherapy. Although OC
is sensitive to chemotherapy, the 5-y survival is 46% for all
stages of OC, and only 20% and 6% for advanced stage III and
IV disease,1 respectively. In the last decades, only slight
improvements have been made to increase patient outcomes,
so there is an unmet need for novel therapeutic strategies as
most women with relapsed or metastatic OC ultimately die of
progressive disease.
Adoptive cell therapy (ACT) exploiting allogeneic natural
killer (NK) cells could be a novel, relatively non-toxic, and
attractive treatment approach against OC. In particular, intra-
peritoneal (i.p.) infusion, rather than intravenous (i.v.)
administration, of pre-activated or expanded NK cells is a
promising strategy to better control ovarian tumors conﬁned to
the peritoneal cavity.2, 3 However, effective ACT requires NK
cells to be appropriately activated, available in sufﬁcient num-
bers, and have a good persistence in vivo.4 Furthermore, effec-
tive NK cell inﬁltration into solid tumor tissue and tumor cell
killing upon encounter is required. Generally, allogeneic NK
cell products have been enriched from peripheral blood (PB) of
haplo-identical donors followed by overnight activation with
IL-2 or IL-15. However, this cellular product is rather heteroge-
neous with 25–95% of infused cells being NK cells depending
on the used enrichment method and contains a variable num-
ber of monocytes, B cells, and potentially alloreactive T cells
capable of inducing graft-versus-host disease.5-7 Furthermore,
this approach yields relatively low NK cell numbers, enough for
only a single dose, while higher numbers and multiple dosing
require further expansion before adoptive transfer.4 For these
reasons, development of more homogeneous, scalable and
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“off-the-shelf” allogeneic NK cell products is preferable for
adoptive immunotherapy.
Alternatively, NK cells can be generated ex vivo from haema-
topoietic stem and progenitor cells (HSPC) or induced pluripo-
tent stem cells (iPSC).3,8-10 Previously, we reported good
manufacturing practice (GMP)-compliant, cytokine-based cul-
ture protocols for the ex vivo generation of highly active NK cells
from CD34C HSPCs isolated from various stem cell sources.9-12
By applying the aryl hydrocarbon receptor (AHR) antagonist
StemRegenin-1 (SR1) and the combination of IL-15 and IL-12,
we demonstrated that highly active CD56C NK cells can be gen-
erated with potent functional activity toward hematological
tumor cells in vitro as well as anti-leukemic effects in vivo follow-
ing i.v. administration.9,10,13 In addition, we observed that these
HSPC-NK cells efﬁciently kill melanoma cell lines12 and renal
cell carcinoma cell lines in vitro (unpublished), and therefore
HSPC-NK cells are attractive for allogeneic NK cell ACT against
refractory OC and other solid tumors.
Many studies, including ours, have shown that pre-activated
or expanded NK cells rapidly recognize and destroy malignantly
transformed cells in vitro.2,3,7,9,10,12-22 However, the majority of
reported studies is based on tumor cell monolayer culture sys-
tems neglecting the three-dimensional (3D) tumor structure,
thereby allowing only limited translation to the in vivo situation.
Therefore, 3D multicellular tumor spheroid models have been
developed to better investigate inﬁltration and intra-tumoral
cytotoxicity by NK cells.15,16,23 Furthermore, adoptive transfer
studies should be performed in relevant human OC xenograft
models to study the optimal delivery route, in vivo persistence of
function and potency of well-deﬁned NK cell products. Recently,
Hermanson et al. demonstrated in a mouse model with the OC
cell line MA148 that i.p. delivery of iPSC-derived NK cells inhib-
its tumor growth at least as efﬁcient as PB-enriched NK cells.3 In
the present study, we investigated the preclinical efﬁcacy of ex
vivo generated, highly functional HSPC-NK cells generated by a
novel combined SR1/IL-15/IL-12-based culture protocol in clin-
ically relevant OC models. Flow cytometry (FCM) analysis and
live-imaging confocal microscopy demonstrate that these
HSPC-NK cells efﬁciently inﬁltrate, migrate, and kill OC cells in
3D tumor spheroids. Moreover, we demonstrate that i.p. infu-
sions of this HSPC-NK cell product mediate a potent anti-OC
effect in an SKOV-3-based xenograft model and signiﬁcantly
prolong mice survival. These preclinical studies provide the
rationale to pursue clinical trials using adoptive transfer of
HSPC-NK cells in OC patients.
Material and methods
HSPC-NK cell generation
Umbilical cord blood (UCB) units were collected in CB-collect
bags (Fresenius Kabi) at caesarean sections after full term preg-
nancy and informed consent was obtained of the mother
(CMO 2014-226). CD34C HSPCs were isolated from mononu-
clear cells after Ficoll–Hypaque density-gradient centrifugation
and CD34-positive immunomagnetic bead selection (Miltenyi
Biotec, 130046702). After isolation, CD34C HSPCs were cryo-
preserved or directly used for NK cell generation. Cultures
were performed for 6 weeks in six-well tissue culture plates
(Corning CLS3506), using CellGro DC medium (CellGenix
20801–0500) supplemented with 10% and 2% human serum
(Sanquin Bloodbank) during the expansion and the differentia-
tion phase, respectively. Cells were cultured using three succes-
sive cytokine cocktails, and in the presence of 2 mM SR1
(Cellagen Technology, C7710–5) till day 21. In the ﬁrst 9 d,
CD34C HSPCs were expanded with 25 ng/mL IL-7, 25 ng/mL
stem cell factor (SCF), 25 ng/mL Flt3L (all ImmunoTools,
11340077, 11343328, 11343307), and 25 ng/mL thrombopoie-
tin (TPO; CellGenix, 1417–050). At day 9, TPO was replaced
by 50 ng/mL IL-15 (ImmunoTools, 11343615). Thereafter,
expanded cells were cultured in differentiation medium consist-
ing of 20 ng/mL IL-7, 20 ng/mL SCF, 50 ng/mL IL-15, and 0.2
ng/mL IL-12 (Miltenyi Biotec, 130–096–704). Total cell num-
ber and CD56 acquisition were analyzed twice a week by ﬂow
cytometry, and medium was refreshed every 2 to 4 d to keep
cell density between 1.5 and 2.5 £ 106 cells/mL. HSPC-NK cell
products were used in experiments after 5 to 6 weeks of culture
with >90% CD56C cells.
Patient samples
Patient material was obtained from stage III and IV OC
patients before primary treatment in the Radboud University
Medical Center (Radboudumc) after written informed consent.
Fresh ascites was ﬁltered using a 100 mm ﬁlter, centrifuged,
and resuspended in phosphate buffered saline (PBS). Subse-
quently, mononuclear cells were isolated using a Ficoll-Hypa-
que (1.077 g/mL; GE Healthcare, 17–1440–03) density
gradient. Samples were cryopreserved in dimethyl sulfoxide
(DMSO)-containing medium and used after thawing.
Culture of OC cell lines
OC cell lines SKOV-3 and IGROV1 were cultured in Roswell
Park Memorial Institute medium (RPMI 1640; Gibco,
11875119) with 10% Fetal Calf Serum (FCS; Integro). The
OVCAR-3 cell line was cultured in RPMI 1640 medium with
20% FCS and 1 mg/mL insulin (Sigma 10516). K562 cells were
cultured in Iscove’s Modiﬁed Dulbecco’s medium (IMDM;
Gibco, 21980065) containing 10% FCS. SKOV-3-GFP-luc cells
were generated by stable transduction of parental cells with len-
tiviral particles LVP20 encoding the reporter genes green ﬂuo-
rescent protein (GFP) and luciferase (luc) under control of the
CMV promoter (GenTarget, LVP020). Transduced cells were
cloned and an optimal SKOV-3-GFP-luc clone for in vitro and
in vivo experiments was selected based on GFP expression,
luciferase activity, and comparable susceptibility to HSPC-NK
killing as the parental cell line.
Multicellular tumor spheroids
OC tumor spheroids were generated by seeding 3 £ 104 cells/
well in a volume of 100 mL/well of culture medium in 96-well
plates coated with 1% agarose in DMEM/F12 medium (Invitro-
gen 11330–057) with 0.3% bovine serum albumin (Sigma
Aldrich A3156), which is adjusted from Giannattasio et al. and
nature protocols.15,24 Tumor spheroids were used for functional
assays upon reaching a solid state after 72 h after initial seeding.
e1320630-2 J. S. HOOGSTAD-VAN EVERT ET AL.
Flow cytometry (FCM)
HSPC-NK cell numbers and expression of cell surface markers
were determined by FCM. Anti-CD45-ECD (Beckman Coulter,
A07784) and anti-CD56-PC7 (BioLegend, 318318) antibodies
were used to follow cell number and NK cell differentiation
during culture using the Coulter FC500 ﬂow cytometer (Beck-
man Coulter). The population of viable cells was determined by
exclusion of 7-amino-actinomycin D (7-AAD) positive cells
(Sigma A9400). For phenotypical analysis, cells were incubated
with antibodies in FCM buffer (PBS/0.5% bovine serum albu-
min) for 30 min at 4C. After washing, cells were resuspended
in FCM buffer and analyzed. The following ﬂuorochrome-con-
jugated monoclonal antibodies were used: CD3 A07748, CD14
325604, CD19 302228, CD56 318318, NKG2A A60797, NKp30
325208, NKp44 325108, NKp46 331908, NKG2D 320806,
DNAM-1 559788, TRAIL 308210, CD69 310904, CD16
302006, KIR’s 312606, CXCR3 353708, CD62L 304821, CD11a
301206, CD107a 328618, HLA-ABC 311410, HLA-E 342603,
MIC A/B 320908, ULBP-1 FAB1380A, ULBP-2 FAB1298P,
TRAIL-R1 307208, TRAIL-R2 307406, CD112 337410, and
CD155 FAB25301A all Biolegend, R&D systems, e-bioscience
or BD Biosciences.
The analysis of NK cell reactivity at the single cell level was
determined following 4 h stimulation with K562 cells in the pres-
ence of anti-CD107a and Brefeldin A (555029 BD Biosciences)
and subsequent intracellular staining for perforin (308106, Biole-
gend) and IFNg (554700 BD Biosciences) and EOMES (11–
4877–41 e-bioscience). Flow cytometric analysis was performed
with exclusion of dead cells with Fixable Viability Dye eFluor780
(65–0865–18 eBiosciences), gating on CD56CPerforinC NK cells,
and using unstimulated cells as control.
FCM- based cytotoxicity and inﬁltration assays
In monolayer cytotoxicity assays, tumor cells were ﬁrst
seeded at a concentration of 3 £ 104 in ﬂat-bottom 96-well
plates in triplicate for each test condition. The following
day, HSPC-NK cells were labeled with 1 mM carboxyﬂuor-
escein diacetate succinimidyl ester (CFSE; Invitrogen,
C34554) and were added at different effector-to-target (E:T)
ratios (1:1, 3:1 and 10:1). For cytotoxicity assays with
SKOV-3-GFPluc cells, HSPC-NK cells were added without
CFSE staining. After 24 h, co-culture supernatants were
harvested and stored at ¡20C until use for enzyme-linked
immunosorbent assay (ELISA). Subsequently, cells in each
well were gently resuspended and suspension cells were col-
lected in Micronics tubes. Next, adherent cells were
detached using trypsine, collected, and added to the tubes.
Then, the life/dead marker 7-AAD was added to the cells
and absolute numbers of viable targets present in each well
were determined by FCM (FC500, Beckman Coulter). The
speciﬁc killing of OC cells by NK cells was calculated with
the following formula: 1 ¡ (number of viable target cells
after co-culture with NK cells/number of viable target cells
cultured alone) £ 100%.
In cytotoxicity assays with OC spheroids, day 3 spheres were
used as described previously by Giannattasio et al.15 Again,
HSPC-NK cells were added at different dosages 2 £ 105, 6 £
105, 2 £ 106/well. After 24 h of co-culture, supernatant of the
2 £ 105 NK cells was collected for ELISA. Spheroids were
washed, and trypsinized and double negative target cells for
CFSE and 7-AAD were counted using the FC500 ﬂow
cytometer.
In the co-culture supernatants, production of granzyme B
(GzmB) and IFNg by HSPC-NK cells was evaluated by ELISA
according to the manufacturer’s instructions (IFNg; Perbio Sci-
entiﬁc M700A and GzmB; Mabtech, 3485–1H-20).
For the FCM-based inﬁltration assay, we performed the
spheroid cytotoxicity assay as described above. Inﬁltrating vs.
non-inﬁltrating HSPC-NK cells were collected separately as
described previously by Giannattasio et al.15 For this, after ﬁxed
time point, supernatant was ﬁrst collected containing the non-
inﬁltrated NK cells. Subsequently, remaining spheroids were
washed twice, trypsinized, and transferred in separate tubes. In
this cell suspension of the spheroid are the inﬁltrated NK cells.
Absolute NK cell counts were determined by FCM for each
well at different time points in supernatant (contains non-inﬁl-
trating HSPC-NK cells) and cell suspension after trypsinization
(contains inﬁltrated HSPC-NK cells).
Intra-tumoral cytotoxicity of inﬁltrated HSPC-NK cells was
determined by transferring HSPC-NK cell treated spheres after
5 h of co-culture to a new well, and subsequently determining
the speciﬁc killing after overnight incubation.
Confocal microscopic imaging of NK cell invasion
and killing in multicellular spheroids
Co-culture of OC spheroids and HSPC-NK cells was performed as
described above. For confocal experiments, SKOV-3-GFPluc sphe-
roids were co-cultured with CD56-APC and GAM-AF647 labeled
NK cells. After co-culture, spheres were collected, washed mildly
with PBS/BSA buffer, and placed in an Ibidi m-slide eight-well
plate (Ibidi, 80826) in RPMI without phenol red, and Propidium
idodide (PI) (Sigma-Aldrich, 247–081–0) was added to a ﬁnal con-
centration of 50 mg/mL to detect cell death. Imaging was per-
formed with a Leica TCS SP5 microscope (Leica Microsystems,
Germany) at 37C using an HC PL Fluotar 20.0 £ 0.5 dry lens.
Laser power, gain and offset were kept constant between experi-
ments and conditions. End point experiments were performed at
0, 1, 3, and 5 h and z-stacks of confocal sections were acquired
with a step size of 5mm. Time lapse movies were made by imaging
with a time interval of 30 s and a maximum acquisition time of
»5 h in a ﬁxed z-plane. GFP and PtdIns were excited with the
argon laser line at 488 nm and emission was detected between 495
and 550 nm for GFP and between 595 and 640 nm for PtdIns. In
a sequential scan APC and GAM-AF647 were excited with the
HeNe laser at 633 nm, and emission was measured between
640 nm and 710 nm.
Image analysis
The acquired images were analyzed with Fiji image analysis
software.25 For qualitative representation, the brightness
and contrast settings were adjusted for better visualization.
The same settings were used for all images. Cell death was
quantiﬁed by placing a threshold on the PtdIns channel
and creating a binary image for every z-plane. Subsequently,
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particles were separated by performing a dilute, erode, and
watershed operation on the image. For every z-plane, a sep-
arate region-of-interest (ROI) was drawn around the edge
of the spheroid, based on the image in the GFP channel.
The area of each ROI was measured and the number of
particles bigger than 20 mm2 was counted. To correct for
size differences between different z-planes and spheroids,
the ratio between the number of particles and the measured
area was used to represent cell death. Cell death in depth
was measured on the 5h HSPC-NK cell co-culture sphe-
roids, and the 250 min time lapse was used for the analysis
of cell death in time and compared with time points in
untreated spheres.
Adoptive transfer studies of HSPC-NK cells
in intraperitoneal OC mouse model
All experiments were approved by the Radboudumc animal
care and user committee (DEC 2014-150). In the ﬁrst experi-
ment, 11 NOD/SCID/IL2Rgnull mice (Jackson laboratories) of
6-12 week old were injected intraperitoneally (i.p.) with 1.0 £
106 cells SKOV-3-GFP-Luc cells and divided randomly into
two treatment groups (i.e., control vs. NK i.p.), after the ﬁrst
BLI at day 3. After 4 and 11 days, mice of the i.p. treatment
group received two i.p. HSPC-NK cell infusions (12 £ 106
cells/mouse/infusion). In addition treated mice received 1 mg
recombinant human IL-15 (Immunotools, 11340158) subcuta-
neously every 48 h till day 21. Bioluminescence images were
collected weekly till day 56. For this, mice were injected i.p.
with D-luciferin 150 mg/kg (PerkinElmer 122796), after
10 min anesthesized with isoﬂurane and bioluminescence
images were collected in the IVIS using the Living Image proc-
essing software. ROI were drawn around the abdominal area of
the mice, and measurements were automatically generated as
integrated ﬂux of photons (photons/s). The second experiment
was performed with a lower tumor dose of 0.2 £ 106 SKOV-3-
GFPLuc cells and again two infusions of 12 £ 106 HSPC-NK
cells were given. Bioluminescence images were collected weekly
till day 56. Blood collection was performed till day 35 by tail
puncture. After erylysis, the ﬂowcytometric analysis of human
CD45C cells vs. mouse CD45 cells was performed to calculate
the percentage of human CD56C cells. All mice were followed
till day 92 for survival. Following euthanasia, a macroscopic
tumor score was given by two independent researchers using
the following classiﬁcation: 0 for no macroscopic tumor, 1 for
small tumors <5 mm and 2 for large tumors  5 mm. From
parafﬁn-embedded samples, 5-mm tissue sections were cut and
placed on polylysine-coated glass slides for immunohistochem-
istry. The method described by Taylor et al. was used for Ki67
staining.26
Statistics
Data analysis was conducted by Prism software (GraphPad,
version 5.03 for Windows). Two-way ANOVA or Student t-
test was used to calculate statistically signiﬁcant differences
between groups. The survival probability was estimated by the
Kaplan–Meier methods, and p-value was calculated with a log-
rank Mantel–Cox test. A p-value of < 0.05 was considered sta-
tistically signiﬁcant.
Results
Ex vivo generation of highly functional HSPC-NK cells
We showed recently that inhibition of the AHR using SR1
improves NK cell generation from CD34C HSPCs by enhanc-
ing the expression level of several transcription factors
involved in early NK cell development.10 In addition, we
reported that combining IL-15 with IL-12 drives the differen-
tiation of more mature and highly functional HSPC-NK cells,
which display potent alloreactivity toward haematological
cancer cells.9 In the present study, we combined SR1, IL-15,
and IL-12 to generate HSPC-NK cells and test their tumor-
reactivity against OC. As illustrated in Fig. 1, this culture
protocol resulted in >1,000-fold expansion and differentia-
tion into >80% CD45CCD56CCD3¡ cells before washing,
after washing even >90% (Fig. 1A and Table S1). Non-
CD56C cells present in the ﬁnal product were comprised of
CD14C myeloid cells and <0.05% CD19C B cells (Fig. 1B).
Contaminating T cells were virtually absent (< 0.05%). After
6 weeks of culture, NK cell yields were determined using
CD56 and NKG2A markers, which discriminated between
conventional EOMESCPerforinC NK cells and other innate
lymphoid cells (Fig. 1B). On average, the SR1/IL-15/IL-12
culture protocol yielded 1,097 £ 106 CD56C cells calculated
from 1 £ 106 CD34C cells (range 833–1,843, n D 7,
Table S1). These cells displayed a high expression level of
activating receptors (Fig. 1C). The expression proﬁle of other
maturation markers, as well as homing and adhesion mole-
cules was similar to that previously reported on HSPC-NK
cell products generated either in the presence of SR1 or IL-
15/IL-12 combination.9,10 Furthermore, these novel SR1/IL-
15/IL-12-induced HSPC-NK cells demonstrated high cyto-
lytic activity and IFNg production capacity against K562 cells
at low E:T ratios (Fig. 1D). Potent NK cell activation and
reactivity was further conﬁrmed at the single cell level with
induction of signiﬁcant proportions of degranulating
CD107aC and IFNgC NK cells upon short-term stimulation
(Fig. 1E). These data show that SR1/IL-15/IL-12-induced
HSPC-NK cells can be generated at high numbers and are
highly functional, providing a strong rationale for HSPC-
NK-cell based immunotherapy.
HSPC-NK cells efﬁciently kill ovarian carcinoma cells
To explore the potential of HSPC-NK cells against OC, we
ﬁrst performed cytotoxicity assays with several frequently
used OC cell lines (SKOV-3, IGROV1, and OVCAR-3). The
NK-sensitive K562 cells were included as a positive control.
At an E:T ratio of 1:1, 24–79% killing was observed after
overnight co-culture (Fig. 2A). This was increased to >90%
using higher E:T ratios and potent killing capacity was seen
for all used HSPC-NK cell products that were generated
from different UCB donors. To further demonstrate high
reactivity of HSPC-NK cells toward OC cells, ELISA for
IFNg and GzmB were performed on co-culture supernatants.
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HSPC-NK released substantial amounts of these factors upon
culture with all three OC cell lines (Fig. 2B and C). Notably,
the levels of IFNg and GzmB released by HPSC-NK cells
against SKOV-3 cells were lower than with the other OC cell
lines. This was also in line with the relatively lower killing
susceptibility of SKOV-3 cells by HSPC-NK cells compared
with IGROV1 and OVCAR-3. To investigate whether this is
related to the expression of certain activating NK-ligands,
we performed FCM analysis of the used OC cell lines and
compared them with EpCAMC OC cells in ascites samples
of 10 different patients. This analysis showed that OC cell
lines and patient’s OC cells in ascites have similar levels of
the NK-activating ligands including MICA/B, ULBP-1,
ULBP-2, DNAM1 ligands (CD112, CD155) and TRAIL
receptors (Fig. 2D and E). Together these data demonstrate
that OC cells display expression of NK-activating ligands
and are highly susceptible to killing by SR1/IL-15/IL-12
induced HSPC-NK cells. From these data, we have chosen
SKOV-3 with the lowest NK-sensitivity as a clinically rele-
vant model for further studies.
Figure 1. SR1/IL-15/IL-12-induced HSPC-NK cells can be generated at high numbers and are highly functional. (A) Fold expansion of seven HSPC-NK cell products cultured
for 40 d depicted as the mean with SD in the upper half. In the lower half, the percentage of CD56C cells counted by ﬂow cytometry is depicted as the mean with SD. (B)
Representative FCM dot plots of an SR1/IL-15/IL-12-generated HSPC-NK cell product with high frequency of CD56C, NKG2AC, perforinC, and EOMESC conventional NK
cells. (C) Histograms illustrating the high expression level of activating receptors on SR1/IL-15/IL-12 generated HSPC-NK cell products. (D) SR1/IL-15/IL-12-induced HSPC-
NK cells demonstrated high cytolytic activity (left ﬁgure) and IFNg production (right ﬁgure) against K562 cells at a low E:T ratio of 1:1, t-test 0.001. (E) Reactivity is shown
at the single cell level with the induction of signiﬁcant proportions of degranulating CD107aC and IFNgC NK cells upon short-term stimulation with K562 target cells in a
representative FCM dot-plot.
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Ovarian carcinoma spheroids are effectively inﬁltrated
and attacked by HSPC-NK cells
To investigate the potency of HSPC-NK cells to inﬁltrate and
kill OC cells in a more physiologic assay for OC deposits, we
set up an OC spheroid culture system using SKOV-3 cells
(Fig. 3A). Plating of SKOV-3 cells in agarose-coated plates
resulted in the formation of well-deﬁned spheroids within 72 h
(Fig. 3B and C), which were used to test HSPC-NK cell killing
and inﬁltration capacity. After overnight incubation (18 h), NK
cell clustering around the spheres was evident and addition of
higher NK cell numbers resulted in disruption of the spheroids
(Fig. 3C). Accordingly, FCM analysis of the co-cultures after
24 h conﬁrmed a dose response relationship between the
amount of NK cells added and the percentage killing of OC
cells, resulting in to >90% target cell killing after co-culture
with 2 £ 106 HSPC-NK cells (Fig. 3D). Furthermore, HSPC-
NK cells signiﬁcantly secreted IFNg and GzmB upon co-cul-
ture with SKOV-3 spheroids (Fig. 3E and F).
Next, we studied whether lysis of OC cells by HSPC-NK cells
occurred primarily from the outside or also within the core of
the spheroids. To address this, we examined NK cell inﬁltration
in time by FCM and confocal microscopy. First, we performed
an FCM-based inﬁltration assay and showed that about one-
third of the added HSPC-NK cells inﬁltrate into the spheroid,
which was similar after co-culture with different amounts of
HSPC-NK cells (Fig. S1). This observation indicates that at
higher HSPC-NK cell numbers, more NK cells will invade into
the tumor spheroids resulting in higher intratumoral killing and
destruction. Following a more extensive washing protocol to
exclude the disrupted outer part of the spheroid, we demon-
strated progressive inﬁltration of the spheroids by HSPC-NK
cells peaking at 8 h (Fig. 4A). After 24 h, less inﬁltrating NK
cells were detected, likely due to disruption of the spheroid as a
consequence of HSPC-NK cell-mediated tumor cell killing.
To demonstrate that the inﬁltrated HSPC-NK cells actually
kill SKOV-3 cells inside the spheroid, we collected and washed
the co-cultured spheroids after 5 h, and transferred them to a
new well for an overnight killing assay, thus without NK cells
in the supernatant. Notably, after initial administration of 2 £
105 HSPC-NK cells, no killing was measured (Fig. 4B). How-
ever, at higher E:T ratios with 6 £ 105 HSPC-NK cells >50% of
SKOV-3 target cells were killed by the inﬁltrated HSPC-NK
cells. To further visualize HPSC-NK cell inﬁltration into the
multicellular SKOV-3 spheroid, we performed time-lapse imag-
ing with confocal microscopy. Already after 1 h of co-culture,
inﬁltrating and migrating CD56C cells were observed in the
outer third of the 500 mm diameter sphere. Gradually, HSPC-
NK cell numbers increased in the outer area, while migrating
NK cells reached the core of the sphere after 5 h of co-culture
(Fig. 4C). Time-lapse movies demonstrated that HSPC-NK
cells actively migrate into the SKOV-3 spheroid and mediate
killing inside the spheroid (Video S1 and S2).
Quantiﬁcation by using the propidium iodide (PtdIns) sig-
nal during co-culture showed that dead SKOV-3 cells were
found in the outer 5–15 mm of the spheroid, but SKOV-3 cell
death was also signiﬁcantly observed up to 60 mm within the
spheroid (i.e., detection limit confocal microscopy; p < 0.0001
compared with untreated spheres; Fig. 4D). At 5 h, the amount
of PtdIns-positive cells per nm2 increased 12 times from 5 to
60, while in the untreated SKOV spheres the amount only dou-
bled (Fig. 4E and F). Collectively, these data demonstrate that
HSPC-NK cells efﬁciently migrate, inﬁltrate, and mediate intra-
tumoral killing of OC cells in a tumor spheroid.
Intraperitoneally transfused HSPC-NK cells inhibits OC
progression in vivo
Based on the encouraging data, we obtained in vitro on
HPSC-NK cell mediated killing of OC cells and spheres,
and we next aimed at evaluating the antitumor potential of
HSPC-NK cells in vivo. To achieve this, we established an
OC mouse model by i.p. inoculation of luciferase-expressing
SKOV-3 cells into NSG mice (Fig. 5A). This model resulted
Figure 2. HSPC-NK cells are effective killers of ovarian cancer cell monolayers. (A)
Percentage of speciﬁc lysis after 24 h co-culture of HSPC-NK cells with different OC
cell lines. Graphs represent data of three different UCB-donors. (B) IFNg production
by HSPC-NK cells from different donors against OC cell lines after 24 h co-culture.
(C) Release of GzmB by HSPC-NK cells against OC cell lines after 24 h co-culture.
Graphs represent the mean § SEM of three experiments. (D) Delta of mean ﬂuo-
rescence index of NK-activation markers of SKOV-3 cells vs. tumor cells (EpCAMC)
of 10 patient ascites samples. Data of EPCAMC tumor cells of 10 patients are
depicted as the mean § SEM.
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in SKOV-3 tumor development in ovaries and omentum, as
well as small nodules deposition along the peritoneum (data
not shown). Proliferation of SKOV-3 tumor cells in the
nodules was conﬁrmed by Ki67 staining (Fig. 5B). Because
one requirement for ACT is the homing of the infused cells
to the tumor site, we tested the effect of HSPC-NK cells
infused directly into the peritoneal cavity, the compartment
where OC is located. Subsequently, tumor growth was ana-
lyzed by bioluminescence imaging (BLI). In a ﬁrst experi-
ment, we observed a slight but signiﬁcant reduction of
SKOV-3 cell progression in mice receiving two HSPC-NK
cell injections and IL-15 support till day 28 (Fig. 5C). Next,
we performed a second experiment using a less stringent
model by decreasing the number of SKOV-3 cells injected
by 5-fold to 0.2 £ 106. Here, the effect of HSPC-NK cells
was more pronounced. Weekly measurement of the BLI sig-
nal indicated potent control of SKOV-3 cell progression by
HSPC-NK cells (Fig. 5D). Importantly, these mice had
improved survival as compared with untreated mice
(Fig. 5E). Furthermore, at sacriﬁce at day 92, the HSPC-
NK-treated mice had a signiﬁcant lower macroscopic tumor
score on peritoneal surfaces. These results demonstrate that
HSCP-NK cells are functional following i.p. infusion and
able to efﬁciently target OC depositions in vivo.
Discussion
The overall survival of patients diagnosed with recurrent and
advanced stage ovarian carcinoma has only slightly improved
in the last 20 y despite evolving therapies, illustrating the unmet
need for new treatment modalities.1 Since HLA class I mole-
cules are often downregulated in ovarian carcinoma and
evidence is emerging that OC cells are susceptible to NK cell-
mediated cytotoxicity,27-29 ACT exploiting allogeneic NK cells
can be proposed as a prime candidate and relatively non-toxic
treatment approach for OC patients. Previous studies have
Figure 3. HSPC-NK cells have high cytolytic activity against SKOV-3 spheroids. (A) Experimental design illustrating the formation of SKOV-3 spheroids, NK cell transfer, and
different functional assays performed. (B) H&E staining at 72 h on 4 mm thick section of the SKOV-3 spheroid. (C) Overview of SKOV-3 spheroid co-cultures without (i.e.,
medium control) and with 2£ 104, 6£ 104, and 20£ 104 HSPC-NK cells. Pictures by light microscopy were taken after 1 h co-culture (top panel) and after 18 h co-culture
(bottom panel) . (D) Speciﬁc lysis by HSPC NK cells of SKOV-3 tumor cells within the spheroids at different E:T ratios. Data are shown as mean § SEM of a three experi-
ment. Two-way ANOVA p D 0.02 (E) and (F) GzmB and IFNg production of HSPC-NK cells after 24 h co-culture with SKOV-3 spheroids (unpaired t-test IFNg p D 0.04,
GzmB p D 0.0009).
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Figure 4. HSPC-NK cells inﬁltrate and mediate efﬁcient intratumoral killing in SKOV-3 spheroids. (A) Percentage of inﬁltrated NK cells in SKOV-3 spheroids was measured
by FCM after co-culture with 2 £ 105 NK cells and trypsinization on four different time points. Bars represent mean § SEM of four experiments. Two-way ANOVA p D
0.018 (B) spheroids with inﬁltrated HSPC-NK cells after 5 h of incubation were transferred to a new well to measure the cytotoxic capacity of the inﬁltrated HSPC-NK cells.
On the left, the percentage speciﬁc lysis without transfer is shown, and on the right, the speciﬁc HSPC-NK cell mediated lysis is depicted after 24 h incubation following
transfer to a new well. Unpaired t-test comparing different HSPC-NK cell dosages without transfer shows a p-value of 0.0003, and a p-value of 0.008 comparing the trans-
ferred spheres. (C) Confocal images of an SKOV-3 spheroid incubated with HSPC-NK cells after four time points. The green cells are GFPC SKOV-3 cells and the blue cells
are HSPC-NK cells inﬁltrating in the spheroid. (D) Amount of PtdIns positive SKOV-3 cells in the spheroids following incubation with HSPC-NK cells (in black), and in
untreated spheroids (in gray), per scan depth in mm. Data are shown as mean § SD of a representative experiment. 60 mm is the maximum scan depth for the used con-
focal microscopy. In the NK-treated spheres, the amount of PtdInsC cells is signiﬁcantly higher (two-way anova; p <0.0001). (E) Amount of PtdIns positive SKOV-3 cells in
time within HSPC-NK cell treated spheroid was calculated with the assistance of Fiji image analysis (in black). As control three time points of an untreated SKOV-3 spher-
oid is depicted in gray. SKOV-3 cell death is signiﬁcantly increased within the HSPC-NK cell treated spheroid compared with untreated spheroid (unpaired t-test with the
Welch correction; p D 0.004). (F) Confocal image of SKOV-3 spheroid incubated 5 h with HSPC-NK cells, with addition of PtdIns. On the left, a spheroid without NK addi-
tion is shown, where few PtdIns positive cells are seen, in the middle a spheroid with HSPC-NK cells, where we see more dead cells, and on the left, a zoomed in picture
of a part of the spheroid illustrating the inﬁltration of HSPC-NK cells causing cell death in an SKOV-3 spheroid.
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shown that allogeneic NK cells rapidly recognize and destroy
malignantly transformed OC cells in vitro and in
vivo.2,3,21,22,30,31 Here, we demonstrate that highly functional
HSPC-NK cells generated by an optimized SR1/IL-15/IL-12-
based expansion protocol are very potent killers of OC cells in
relevant preclinical models. Moreover, we provide novel evi-
dence that HSPC-NK cells are able to efﬁciently inﬁltrate,
migrate, and mediate intratumoral killing of OC cells in a mul-
ticellular tumor spheroid and that after i.p. infusion HSPC-NK
cells slows down tumor progression and prolongs survival in
OC-bearing mice.
Collectively, these ﬁndings provide a strong rationale for
intraperitoneal HSPC-NK cell-based therapy against OC. To
generate high numbers of allogeneic NK cells completely
devoid of T cell contamination, we developed a GMP-compli-
ant, cytokine-based, feeder-free ex vivo culture protocols. Using
this procedure, CD34C HSPCs isolated from widely available
UCB units can be expanded over 1,000-fold into a mixture of
Figure 5. Intraperitoneal infusion of HSPC-NK cells slows down tumor growth and improves survival of OC-bearing NSG mice. (A) Experimental design of i.p. SKOV-3 injec-
tion and subsequent adoptive transfer of two HSPC-NK cell infusions combined with rhIL-15 administration till day 21. Tumor load was followed by BLI imaging till day 56
and mice were followed for survival till day 92. (B) Ki67 immunohistochemical staining of intraperitoneal SKOV-3 tumor nodules of NSG mice bearing SKOV-3 tumors,
showing high tumor cell proliferation. (C) Results of the high tumor (1 £ 106 SKOV-3 cells i.p.) dose experiment of the tumor size evaluation by the quantiﬁcation of the
bioluminescent signal (in photons per second per cm2) in a standardized ROI. In red, the BLI signal of mice treated with intraperitoneal HSPC-NK infusions and in black
the untreated mice. HSPC-NK cell treatment signiﬁcantly reduced tumor growth (two-way ANOVA; p D 0.016). (D) Radiance in photons per second per cm2 of the lower
tumor dose experiment with 0.2 £ 106 SKOV-3 cells i.p. HSPC-NK cell treatment signiﬁcantly reduced tumor growth at this lower tumor burden (two-way ANOVA p D
0.0007). (E) Percentage survival of the NSG mice of the low tumor dose experiment. Kaplan meier with the log rank Mantel Cox test showed a signiﬁcance of p D 0.023
and a hazard ratio of 6. (F) Macroscopic tumor score of the NSG mice after sacriﬁcing at day 92 with a signiﬁcantly lower tumor score on peritoneal surfaces after HSPC-
NK cell treatment (Paired t-test; p D 0.034).
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immature and mature NK cells with a purity of > 90%. In this
study, we combined two recent optimizations, which include
the AhR antagonist SR1 for improving NK cell differentiation,
and the combination of IL-15 and IL-12 that stimulates the dif-
ferentiation of more “memory-like” NK cells with a superior
cytolytic and IFNg response upon target cell encounter.9,10
This SR1/IL-15/IL-12 generated HSPC-NK cell product is even
more pure; >90% and a total dosage up to 3 £ 109 HSPC-
NKcells for i.p. infusion in OC patients can be readily generated
from a single HSPC donor. This is a higher purity and yield
than NK products from other sources and protocols.4-6,32,33
These highly active HSPC-NK cells rapidly recognize and
destroy malignantly transformed cells in vitro when added to
tumor cell monolayers. Although tumor monolayer cell culture
is traditionally used,2,3,17,33,34 it neglects the 3D tumor struc-
ture, thereby potentially overestimating the translation to the
in vivo situation. Therefore, 3D tumor spheroid models have
been developed to better investigate solid tumor-NK cell
interactions, and more closely resemble the tumor microenvi-
ronment than conventional monolayer cultures. These multi-
cellular tumor spheroids are formed by the association of
several thousands of cells and consist of an outer rim of prolif-
erating cells around a core of quiescent tumor cells.14 So far, a
few studies are published using tumor spheroids to assess NK
cell inﬁltration and intratumoral cytoxicity dynamics. Giannat-
tasio et al. showed that IL-2 pre-activated and expanded PB-
NK cells can invade cervical cancer spheroids.15 We have
adopted the spheroid system of Giannattasio et al. and showed
by real-time monitoring that inﬁltrated HSPC-NK cells in OC
spheroids mediate efﬁcient intratumoral killing, which is of
clinical relevance for HSPC-NK cell therapy in OC treatment.
However, still many questions remain unanswered about the
mechanism of action of activated NK cells in solid tumors. Fur-
thermore, previous studies showed that 3D tumor spheroids
are useful tools to study the stimulatory potential of other drugs
and cells of the tumor microenvironment on NK cell function.
For instance, inhibition of NK cell function in Ewing’s sarcoma
spheroids23 and head and neck squamous cell carcinoma
(HNSCC) spheroids16 was reported. Interestingly, cetuximab,
an anti-epidermal growth factor receptor (HER1) antibody,
reconstituted pro-inﬂammatory cytokine secretion and tumor-
inﬁltrating capacity of sMICA-inhibited NK cells in HNSCC
spheroids.16 In addition, Herter et al. recently used a 3D spher-
oid model composed of tumor cells, ﬁbroblast, and immune
cells to study the effect of combined treatment with a novel
IgG-IL2v compound and tumor-targeting bispeciﬁc antibody.35
Finally, we and Giannattasio et al. show that efﬁcient tumor
spheroid inﬁltration is performed by only a fraction of the acti-
vated NK cells. This could be related to differential phenotypes
of inﬁltrating and non-inﬁltrating NK cells. Moreover,
although some activated NK cells can kill up to 14 adjacent
tumor cells within 6 h, each NK cell within a bulk population
or product is not equally active in forming contacts and serial
killing properties.17,18 Therefore, further studies are warranted
to decipher the behavior of individual HSPC-NK cells in differ-
ent models; looking at inﬁltration in 3D tumor spheroids or
even at in vivo behavior in intravital multiphoton microscopy
in adoptive transfer studies in OC-bearing mice.36
Regarding the potency of HSPC-NK cells to target OC in
vivo, we observed that two i.p. infusions plus IL-15 support
inhibited tumor growth prolonged survival and resulted in a
lower macroscopic tumor score in SKOV-3 bearing NSG mice.
The localization of tumor depositions in the SKOV-3 tumor
xenograft model in omentum, ovaries, and peritoneal surfaces
makes the model clinically relevant. Through intraperitoneal
infusion of highly active HSPC-NK cells, direct targeting of the
tumor cells is facilitated. Important is the effect that is shown
on the peritoneal surfaces, since omentum and ovaries are
removed during surgery. Tumor depositions on the peritoneum
are difﬁcult to resect, often causing incomplete debulking and
therefore important in prognosis of OC patients.
Good inﬁltration rates are considered a critical factor for
effective adoptive NK cell therapy.37 In a bladder cancer mouse
model, intravesical NK cell administration shows a signiﬁcant
higher inﬁltration rate than systemic delivery.33 Furthermore,
investigators at the University of Minnesota have clearly demon-
strated in a mouse model with the OC cell line MA148 that the i.
p. delivery route of activated NK cells is superior to i.v. infusion
for an effective anti-OC effect.2,3 Previously, we and others have
observed that a large proportion of activated NK cells are trapped
in the liver upon i.v. infusion,13,38,39 and therefore i.p. infusion of
a high dose of HSPC-NK cells can immediately attack the OC
cells as NK sequestration in the liver will be prevented.
Although we have observed signiﬁcant anti-OC effects of
HSPC-NK cells in SKOV-3 tumor spheroids and xenograft
models, potentiating of the anti-OC reactivity in vivo might be
needed in patients. Different strategies to improve HSPC-NK
cell-ACT could be explored. For instance, combining HSPC-
NK cell infusion with i.p. administration of the IL-15 supera-
gonist ALT-803 might be promising. ALT-803 has a longer
half-life than rhIL-15 and represents an effective IL-15 recep-
tor-agonist that augments NK cell proliferation, cytotoxic
potential and antibody-dependent cell-mediated cytotoxicity
(ADCC).19 Other factors that might enhance the anti-OC effect
are to be investigated, especially combination therapy with
tumor-targeting antibodies or immune modulatory agents
seems promising. ADCC is attractive because of the rapidly
upregulated CD16 expression of our HSPC-NK cell product in
vivo and cytotoxic anti-OC activity could be enhanced with a
targeted antibody.9 Similar to cytotoxic T cells, chimeric antigen
receptor-mediated antitumor activity has been demonstrated
using different NK cell sources and might provide a method to
redirect these cells more speciﬁcally to target refractory can-
cers.34 Another option to improve HSPC-NK cell therapy is to
sensitize tumor cells to NK cell mediated killing by combined
treatment with hypomethylating agents such as decitabine.40
In conclusion, our data strongly support that SR1/IL–15/
IL12 expanded HSPC-NK cells constitute a promising immu-
notherapeutic product that can be exploited for intraperitoneal
therapy of OC patients, as demonstrated by their capability to
actively migrate, inﬁltrate, and mediate intratumoral cell killing
in OC spheroids. In addition, we demonstrated promising pre-
clinical anti-OC activity of HSPC-NK cells following intraperi-
toneal infusion in a relevant SKOV-3-based OC xenograft
model. Finally, the methodologies reported here to study
HSPC-NK cell inﬁltration capacity and anti-OC effects will be
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instrumental to validate future combination therapies for the
treatment of refractory or relapsed OC patients.
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